https://www.jnj.com/media-center/press-releases/late-breaking-phase-2-data-for-investigational-oral-factor-xia-inhibitor-milvexian-suggest-favorable-antithrombotic-profile-across-a-wide-range-of-doses
Milvexian demonstrated efficacy and no increase in bleeding across doses with no major bleeds in the milvexian arms, when compared with enoxaparin, for...
factor xialatebreakingphasedata